OncoPep, Inc.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer (NCT04634747) | OncoPep, Inc. | 2022-04-30 |
Track OncoPep, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.